Prothena

PRTA · NASDAQ

$8.50+$0.02 (+0.24%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $8.48

Latest news

Press releaseSep 9, 4:05 PM ETBusiness Wire
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Press releaseAug 6, 4:05 PM ETBusiness Wire
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
Press releaseJul 30, 4:05 PM ETBusiness Wire
Prothena to Report Second Quarter 2026 Financial Results on August 6
NewsMay 7, 4:11 PM ET
Prothena Corp Q1 EPS $0.60 Beats $(0.34) Estimate, Sales $51.084M Beat $1.010M Estimate
Press releaseMay 7, 4:05 PM ETBusiness Wire
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
Press releaseApr 30, 4:05 PM ETBusiness Wire
Prothena to Report First Quarter 2026 Financial Results on May 7
Press releaseApr 27, 4:05 PM ETBusiness Wire
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
Press releaseApr 10, 4:05 PM ETBusiness Wire
Prothena Announces Leadership Team Updates
Press releaseMar 21, 4:05 PM ETBusiness Wire
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026
Press releaseMar 9, 4:05 PM ETBusiness Wire
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
Press releaseFeb 27, 4:15 PM ETBusiness Wire
Prothena Announces up to $100 Million Share Repurchase Plan
NewsFeb 19, 4:14 PM ET
Prothena Corp Q4 Earnings Assessment
Press releaseFeb 19, 4:05 PM ETBusiness Wire
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
NewsFeb 19, 6:11 AM ET
Earnings Scheduled For February 19, 2026
NewsFeb 18, 3:01 PM ET
Exploring Prothena Corp's Earnings Expectations
Press releaseFeb 12, 4:05 PM ETBusiness Wire
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Press releaseDec 12, 4:05 PM ETBusiness Wire
Prothena Announces Board of Directors Update
NewsDec 1, 9:42 AM ETAvi Kapoor
Amazon To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday
Press releaseNov 19, 4:05 PM ETBusiness Wire
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
NewsNov 12, 9:24 AM ETVandana Singh
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker
Press releaseNov 11, 9:00 AM ETBusiness Wire
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
Press releaseNov 6, 4:05 PM ETBusiness Wire
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
Press releaseOct 30, 4:05 PM ETBusiness Wire
Prothena to Report Third Quarter 2025 Financial Results on November 6
NewsOct 7, 5:01 PM ET
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings)
NewsOct 1, 5:12 PM ET
Prothena's Partner Bristol Myers Squibb Receives Fast Track Designation From The FDA For BMS-986446 For The Treatment of Alzheimer's Disease
Press releaseOct 1, 4:45 PM ETBusiness Wire
Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease
NewsAug 29, 10:09 AM ETVandana Singh
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy
Press releaseAug 28, 4:05 PM ETBusiness Wire
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
NewsAug 28, 1:37 PM ETVandana Singh
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study
NewsAug 28, 9:00 AM ET
What 4 Analyst Ratings Have To Say About Prothena Corp
Press releaseAug 27, 4:05 PM ETBusiness Wire
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
Press releaseAug 6, 9:00 AM ETBusiness Wire
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
NewsAug 5, 8:07 AM ET
9 Analysts Assess Prothena Corp: What You Need To Know
Press releaseAug 4, 4:05 PM ETBusiness Wire
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
NewsAug 1, 5:05 PM ET
A Glimpse of Prothena Corp's Earnings Potential
Press releaseJul 28, 4:05 PM ETBusiness Wire
Prothena to Report Second Quarter 2025 Financial Results on August 4
Press releaseJun 16, 1:06 AM ETBusiness Wire
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
Press releaseFeb 20, 4:05 PM ETBusiness Wire
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
Press releaseSep 27, 4:05 PM ETBusiness Wire
Prothena Announces Leadership Team Updates
Press releaseAug 8, 4:05 PM ETBusiness Wire
Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

Prothena to Report Second Quarter 2026 Financial Results on August 6

Prothena Corp Q1 EPS $0.60 Beats $(0.34) Estimate, Sales $51.084M Beat $1.010M Estimate

Prothena Reports First Quarter 2026 Financial Results and Business Highlights

Prothena to Report First Quarter 2026 Financial Results on May 7

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Prothena Announces Leadership Team Updates

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

Prothena Announces up to $100 Million Share Repurchase Plan

Prothena Corp Q4 Earnings Assessment

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

Earnings Scheduled For February 19, 2026

Exploring Prothena Corp's Earnings Expectations

Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Prothena Announces Board of Directors Update

Amazon To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Earnings Scheduled For November 6, 2025

Prothena to Report Third Quarter 2025 Financial Results on November 6

Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings)

Prothena's Partner Bristol Myers Squibb Receives Fast Track Designation From The FDA For BMS-986446 For The Treatment of Alzheimer's Disease

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study

What 4 Analyst Ratings Have To Say About Prothena Corp

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

9 Analysts Assess Prothena Corp: What You Need To Know

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

A Glimpse of Prothena Corp's Earnings Potential

Prothena to Report Second Quarter 2025 Financial Results on August 4

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena Announces Leadership Team Updates

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights